Volume 9, Issue 1 p. E1-E16
Online Exclusive

Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Keith A. Johnson

Keith A. Johnson

Departments of Radiology and Neurology, Massachusetts General Hospital Harvard Medical School, Boston, MA, USA

Search for more papers by this author
Satoshi Minoshima

Satoshi Minoshima

Department of Radiology, University of Washington, Seattle, WA, USA

Search for more papers by this author
Nicolaas I. Bohnen

Nicolaas I. Bohnen

Departments of Radiology and Neurology, University of Michigan, and VA Ann Arbor Healthcare System, Ann Arbor, MI, USA

Search for more papers by this author
Kevin J. Donohoe

Kevin J. Donohoe

Beth Israel Deaconess Medical Center, Boston, MA, USA

Search for more papers by this author
Norman L. Foster

Norman L. Foster

Department of Neurology, University of Utah, Salt Lake City, UT, USA

Search for more papers by this author
Peter Herscovitch

Peter Herscovitch

PET Department, NIH Clinical Center National Institutes of Health, Bethesda, MD, USA

Search for more papers by this author
Jason H. Karlawish

Jason H. Karlawish

Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Search for more papers by this author
Christopher C. Rowe

Christopher C. Rowe

Department of Nuclear Medicine and Centre for PET, Austin Health, Victoria, Australia

Search for more papers by this author
Maria C. Carrillo

Corresponding Author

Maria C. Carrillo

Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA

Corresponding author. Tel.: +312 335 5722; Fax: +866 741 3716.

E-mail address: [email protected]

Search for more papers by this author
Dean M. Hartley

Dean M. Hartley

Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA

Search for more papers by this author
Saima Hedrick

Saima Hedrick

Society of Nuclear Medicine and Molecular Imaging, Reston, VA, USA

Search for more papers by this author
Virginia Pappas

Virginia Pappas

Society of Nuclear Medicine and Molecular Imaging, Reston, VA, USA

Search for more papers by this author
William H. Thies

William H. Thies

Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL, USA

Search for more papers by this author
First published: 28 January 2013
Citations: 357
© 2013 by the Alzheimer's Association, and the Society for Nuclear Medicine and Molecular Imaging.
This article is being published jointly in Alzheimer's & Dementia, and The Journal of Nuclear Medicine.

Abstract

Positron emission tomography (PET) of brain amyloid β is a technology that is becoming more available, but its clinical utility in medical practice requires careful definition. To provide guidance to dementia care practitioners, patients, and caregivers, the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened the Amyloid Imaging Taskforce (AIT). The AIT considered a broad range of specific clinical scenarios in which amyloid PET could potentially be used appropriately. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these scenarios, and the AIT developed a consensus of expert opinion. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific appropriate use criteria (AUC) were agreed on that define the types of patients and clinical circumstances in which amyloid PET could be used. Both appropriate and inappropriate uses were considered and formulated, and are reported and discussed here. Because both dementia care and amyloid PET technology are in active development, these AUC will require periodic reassessment. Future research directions are also outlined, including diagnostic utility and patient-centered outcomes.